This analysis of pooled data from nine randomized clinical
trials shows that younger (65 years) and older
(C65 years) patients with T2DM achieved similar overall
glycemic control with available treatments. However,
analysis by therapy demonstrates that insulin glargine is
associated with better glycemic control and a reduced
incidence of daytime and any hypoglycemia in both
younger and older T2DM patients than comparators. Similarly, the analysis shows that glycemic control improves to
a greater extent, with lower incidences of daytime and any
hypoglycemia with insulin glargine than comparators,
when the older patients were analyzed by age (65–74 and
C75 years)although the differences were only statistically significant in the former group of patients. Together,
these results suggest that older patients, including the very
elderly, can safely be transitioned to basal insulin regimens
to control progressive disease, with insulin glargine being a
useful option for these patients.
This analysis of pooled data from nine randomized clinicaltrials shows that younger (65 years) and older(C65 years) patients with T2DM achieved similar overallglycemic control with available treatments. However,analysis by therapy demonstrates that insulin glargine isassociated with better glycemic control and a reducedincidence of daytime and any hypoglycemia in bothyounger and older T2DM patients than comparators. Similarly, the analysis shows that glycemic control improves toa greater extent, with lower incidences of daytime and anyhypoglycemia with insulin glargine than comparators,when the older patients were analyzed by age (65–74 andC75 years)although the differences were only statistically significant in the former group of patients. Together,these results suggest that older patients, including the veryelderly, can safely be transitioned to basal insulin regimensto control progressive disease, with insulin glargine being auseful option for these patients.
การแปล กรุณารอสักครู่..